CBIO 8-K: Q3 2025 financial results press release furnished

Rhea-AI Filing Summary

Crescent Biopharma (CBIO) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.

The Company states this information is being furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth. The report is signed by CEO Joshua Brumm.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001253689false00012536892025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________________________________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2025

________________________________________________________________________________________________

Crescent Biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

________________________________________________________________________________________________

Cayman Islands			001-36177			06-1686563
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
300 Fifth Avenue Waltham, MA						02451
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s telephone number, including area code: (617) 430-5595

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Ordinary Shares, $0.001 par value per share

CBIO

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02        Results of Operations and Financial Condition.

On November 6, 2025, Crescent Biopharma, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 and Exhibits 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01        Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.						Description
99.1						Press Release issued by Crescent Biopharma, Inc. on November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRESCENT BIOPHARMA, INC.

Date: November 6, 2025

By:

/s/ Joshua Brumm

Name:

Joshua Brumm

Title:

Chief Executive Officer

FAQ

What did Crescent Biopharma (CBIO) announce in this 8-K?

It furnished a press release with financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Which period do the reported results cover for CBIO?

The quarter ended September 30, 2025.

Where can I find the detailed financial results for CBIO?

In the press release attached as Exhibit 99.1 to the 8-K.

Is the CBIO information considered filed under Section 18?

No. It is furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act.

Who signed the CBIO 8-K and in what capacity?

Chief Executive Officer Joshua Brumm signed the report.

What exchange and ticker does Crescent Biopharma use?

Its Ordinary Shares trade on The Nasdaq Capital Market under ticker CBIO.

What is the date of the CBIO press release referenced?

November 6, 2025.